Home › Funds › Jefferies Financial Group Inc. › URGN
Jefferies Financial Group Inc. position in URGN
UROGEN PHARMA LTD · Health Care
Jefferies Financial Group Inc. reported holding 2,199,652 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$89.4M, representing 1.64% of its reported portfolio and ranking #6 among its reported holdings. Jefferies Financial Group Inc. has disclosed URGN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Jefferies Financial Group Inc.'s URGN position evolved
Jefferies Financial Group Inc. first disclosed a stake in URGN in Q1 2024 at 840,000 shares (US$12.6M). The position peaked in Q3 2026 at 2,199,652 shares, worth US$89.4M. Across 11 filings, Jefferies Financial Group Inc. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 2,199,652 shares valued at US$89.4M. Notable position changes include a 96% trim in Q2 2025 (shares rose 46% over the following quarter), a 7232% increase in Q3 2025 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 840.00K | $12.60M | New |
| Q2 2024 | 965.00K | $16.19M | Add |
| Q3 2024 | 965.00K | $12.26M | Hold |
| Q4 2024 | 965.93K | $10.29M | Hold |
| Q1 2025 | 815.00K | $9.01M | Reduce |
| Q2 2025 | 30.00K | $411.00K | Reduce |
| Q3 2025 | 2.20M | $43.88M | Add |
| Q4 2025 | 2.20M | $51.52M | Hold |
| Q1 2026 | 2.20M | $39.55M | Hold |
| Q2 2026 | 2.20M | $80.95M | Hold |
| Q3 2026 | 2.20M | $89.37M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About URGN and 13F data
URGN (UROGEN PHARMA LTD) is a Health Care company. 44 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), ACORN CAPITAL ADVISORS, LLC (US$61.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding URGN
- RTW INVESTMENTS, LP 4.54M sh · $167.22M · Q2 2026
- Kynam Capital Management, LP 2.43M sh · $89.58M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.67M sh · $61.58M · Q2 2026
- Opaleye Management Inc. 1.44M sh · $52.99M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.15M sh · $46.67M · Q3 2026
- MPM BioImpact LLC 933.41K sh · $34.35M · Q2 2026
- Soleus Capital Management, L.P. 829.81K sh · $30.54M · Q2 2026
- Boxer Capital Management, LLC 500.00K sh · $18.40M · Q2 2026
- NEXT CENTURY GROWTH INVESTORS LLC 297.08K sh · $12.07M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 191.31K sh · $7.04M · Q2 2026
More on Jefferies Financial Group Inc.
FAQ
How long has Jefferies Financial Group Inc. held URGN?
Jefferies Financial Group Inc. has disclosed URGN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Jefferies Financial Group Inc.'s current position in URGN?
As of Q3 2026, Jefferies Financial Group Inc. holds 2.20M shares of URGN (UROGEN PHARMA LTD), valued at $89.37M, representing 1.64% of its reported portfolio and ranking #6.
Has Jefferies Financial Group Inc. been buying or selling URGN?
In the latest 13F filing (Q3 2026), Jefferies Financial Group Inc. held unchanged its position in URGN. The position peaked in Q3 2026 at 2.20M shares.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, ACORN CAPITAL ADVISORS, LLC, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.